Animax

Manufacturer
Dechra Veterinary Products
Effective date
2021-10-21
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-01 22:30:57

Label at a glance#

ProductAnimax
Active ingredientNYSTATIN, NEOMYCIN SULFATE, THIOSTREPTON, TRIAMCINOLONE ACETONIDE
Label structure17 sections

Dosage and administration

  Frequency of administration is dependent on the severity of the condition. For mild inflammations, application may range from once daily to once a week; for severe conditions Animax Cream may be applied as often as 2 to 3 times daily, if necessary. Frequency of treatment may be decreased as improvement occurs. Clean affected areas, removing any encrusted discharge or exudate. Apply Animax Cream (Nystatin-Neomyci...

Storage and handling

  Store at room temperature; avoid excessive heat (104°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

ANADA# 200-330. Approved by FDA.

For topical use on dogs and cats only.

Not for ophthalmic use.

CAUTION:

VETERINARY INDICATIONS SECTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

DESCRIPTION SECTION

Animax Cream combines nystatin, neomycin sulfate, thiostrepton and triamcinolone acetonide.
Each gram contains:

nystatin................................................................................................................ 100,000 units
neomycin sulfate equivalent to neomycin base................................................................ 2.5 mg
thiostrepton ............................................................................................................. 2,500 units
triamcinolone acetonide ................................................................................................... 1 mg

in an aqueous non-irritating vanishing cream base of polyoxyethylene fatty alcohol ether, sorbitol solution, propylene glycol, white petrolatum, polyoxyl 40 stearate, glyceryl monostearate, titanium dioxide, citric acid, ethylenediamine, methylparaben, propylparaben.

ACTIONS:

SPL UNCLASSIFIED SECTION

  1. By virtue of its four active ingredients, Animax Cream (nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide cream USP) provides four basic therapeutic effects: anti-inflammatory, antipruritic, antifungal and antibacterial. Triamcinolone acetonide is a potent synthetic corticosteroid providing rapid and prolonged symptomatic relief on topical administration. Inflammation, edema, and pruritis promptly subside, and lesions are permitted to heal. Nystatin is the first well-tolerated antifungal antibiotic of dependable efficacy for the treatment of cutaneous infections caused by Candida albicans (Monilia). Nystatin is fungistatic in vitro against a variety of yeast and yeast-like fungi including many fungi pathogenic to animals. No appreciable activity is exhibited against bacteria.
    Thiostrepton has a high order of activity against gram-positive organisms, including many which are resistant to other antibiotics; neomycin exerts antimicrobial action against a wide range of gram-positive and gram-negative bacteria. Together they provide comprehensive therapy against those organisms responsible for most superficial bacterial infections.

INDICATIONS:

INDICATIONS & USAGE SECTION

  1. Animax Cream (nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide cream USP) is indicated in the management of dermatologic disorders in dogs and cats, characterized by inflammation and dry or exudative dermatitis, particularly those caused, complicated, or threatened by bacterial or candidal (Candida albicans) infections. It is also of value in eczematous dermatitis, contact dermatitis, and seborrheic dermatitis; and as an adjunct in the treatment of dermatitis due to parasitic infestation.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

  1. Animax Cream should not be used ophthalmically.

WARNINGS:

WARNINGS SECTION

  1. Animax Cream is indicated for use in dogs and cats only. Not for use in animals which are raised for food.
    Absorption of triamcinolone acetonide through topical application and by licking may occur. Therefore animals should be observed closely for signs of polydipsia, polyuria and increased weight gain particularly when the preparation is used over large areas or for extended periods of time.
    Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.
    Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia and anasarca.

PRECAUTIONS:

PRECAUTIONS SECTION

  1. Animax Cream (Nystatin-Neomycin Sulfate- Thiostrepton-Triamcinolone Acetonide Cream USP) is not intended for the treatment of deep abscesses or deep-seated infections such as inflammation of the lymphatic vessels. Parenteral antibiotic therapy is indicated in these infections. Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Cream USP has been extremely well tolerated. The occurrence of systemic reactions is rarely a problem with topical administration.
    Sensitivity to neomycin may occur. If redness, irritation or swelling persists or increases, discontinue use. Do not use if pus is present since the drug may allow the infection to spread.
    Avoid ingestion. Oral or parental use of corticosteroids, depending on dose, duration and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal.

SIDE EFFECTS:

ADVERSE REACTIONS SECTION

  1. SAP and SGPT (ALT) enzyme elevations, polydipsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

  1. Frequency of administration is dependent on the severity of the condition. For mild inflammations, application may range from once daily to once a week; for severe conditions Animax Cream may be applied as often as 2 to 3 times daily, if necessary. Frequency of treatment may be decreased as improvement occurs.
    Clean affected areas, removing any encrusted discharge or exudate. Apply Animax Cream (Nystatin-Neomycin Sulfate- Thiostrepton-Triamcinolone Acetonide Cream USP) sparingly in a thin film.

HOW SUPPLIED:

HOW SUPPLIED SECTION

  1. Animax Cream (nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide cream USP) is supplied in tubes as follows:

7.5 gram tubes NDC 17033-123-75
15 gram tubes NDC 17033-123-15

STORAGE:

STORAGE AND HANDLING SECTION

  1. Store at room temperature; avoid excessive heat (104°F).

TO OPEN:

SPL UNCLASSIFIED SECTION

  1. Use cap to puncture seal.

IMPORTANT:

SPL UNCLASSIFIED SECTION

  1. Do not use if seal has been punctured or is not visible.

SPL UNCLASSIFIED SECTION

MANUFACTURED FOR:
Dechra Veterinary Products
Overland Park, KS 66211

I123 DECHRA R07/08 #288

PRINCIPAL DISPLAY PANEL - 7.5 g Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

ANIMAX® CREAM

nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide cream

NET CONTENTS 7.5 g
ANADA # 200-330. Approved by FDA
NDC 17033-123-75

PRINCIPAL DISPLAY PANEL - 7.5 g Carton
PRINCIPAL DISPLAY PANEL - 7.5 g Carton

PRINCIPAL DISPLAY PANEL - 7.5 g Container

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

  1. NET CONTENTS 7.5 g
    NDC 17033-123-75
    ANIMAX ® CREAM

nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide cream

ANADA # 200-330. Approved by FDA.

PRINCIPAL DISPLAY PANEL - 7.5 g Container
PRINCIPAL DISPLAY PANEL - 7.5 g Container

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NEOMYCIN SULFATEACTIVE INGREDIENT057Y6266931
NYSTATINACTIVE INGREDIENTBDF1O1C72E1
THIOSTREPTONACTIVE INGREDIENTHR4S203Y181
TRIAMCINOLONE ACETONIDEACTIVE INGREDIENTF446C597KA1
NEOMYCINACTIVE MOIETYI16QD7X2971
NYSTATINACTIVE MOIETYBDF1O1C72E1
THIOSTREPTONACTIVE MOIETYHR4S203Y181
TRIAMCINOLONE ACETONIDEACTIVE MOIETYF446C597KA1
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QP1
ETHYLENEDIAMINEINACTIVE INGREDIENT60V9STC53F1
GLYCERYL MONOSTEARATEINACTIVE INGREDIENT230OU9XXE41
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1
POLYOXYL 40 STEARATEINACTIVE INGREDIENT13A4J4NH9I1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH1
SORBITOLINACTIVE INGREDIENT506T60A25R1
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
17033-12317033-123-75, 17033-123-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 455 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPOINTMENT / TOPICAL5 %w/wExact identifier — unii candidate
40 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3DROPS / ORAL200 mg/1mlExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPSUSPENSION / ORAL113 mgExact identifier — unii candidate
40 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / RECTAL1214 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RESPIRATORY (INHALATION)0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHPOWDER / ORALNAExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION / SUBCUTANEOUS0.16 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / INTRAVENOUS45 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / AURICULAR (OTIC)10 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / SOFT TISSUE0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, METERED / RECTALNAExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TELIXIR / ORAL800 mgExact identifier — unii candidate
79 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / INTRAVENOUS396 mgExact identifier — unii candidate
88 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / INTRAMUSCULAR45 mgExact identifier — unii candidate
79 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / AURICULAR (OTIC)0.2 %w/vExact identifier — unii candidate
88 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL / TOPICAL19.2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCREAM, AUGMENTED / TOPICAL15 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
GLYCERYL MONOSTEARATEGLYCERYL MONOSTEARATE230OU9XXE4CAPSULE, DELAYED RELEASE / ORAL15 mgExact identifier — unii candidate
21 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / TOPICAL0.16 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
ETHYLENEDIAMINEETHYLENEDIAMINE60V9STC53FSOLUTION / ORAL18.5 mg/5mlExact identifier — unii candidate
3 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE / ORAL72 mgExact identifier — unii candidate
40 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPTABLET / SUBLINGUAL24 mgExact identifier — unii candidate
88 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / PARENTERAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION/ DROPS / OPHTHALMIC0.25 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPTABLET, EXTENDED RELEASE / ORAL45 mgExact identifier — unii candidate
88 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INFILTRATION80 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INFILTRATION0.35 mgExact identifier — unii candidate
68 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPLIQUID / RESPIRATORY (INHALATION)0.13 %w/wExact identifier — unii candidate
88 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RINJECTION, SOLUTION / SUBCUTANEOUS4.7 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPPOWDER / ORAL2 mgExact identifier — unii candidate
40 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHENEMA / RECTAL0.02 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPPOWDER, FOR SUSPENSION / ORAL840 mgExact identifier — unii candidate
88 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RTABLET, EXTENDED RELEASE / ORAL428 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / VAGINAL3 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
GLYCERYL MONOSTEARATEGLYCERYL MONOSTEARATE230OU9XXE4TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL23 mgExact identifier — unii candidate
21 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, DELAYED RELEASE / ORAL36 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION, CONCENTRATE / INTRAVENOUS50.33 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / INTRAMUSCULAR26 mgExact identifier — unii candidate
88 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USUPPOSITORY / VAGINAL27 mgExact identifier — unii candidate
18 equally ranked IID candidates
GLYCERYL MONOSTEARATEGLYCERYL MONOSTEARATE230OU9XXE4SUSPENSION / AURICULAR (OTIC)0.5 %w/vExact identifier — unii candidate
21 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / AURICULAR (OTIC)0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / PARENTERAL30 mgExact identifier — unii candidate
79 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
88 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSYRUP / ORAL81 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / TOPICAL5.28 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / RESPIRATORY (INHALATION)25 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SYRUP / ORAL5700 mgExact identifier — unii candidate
81 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9ULOTION / TOPICAL25 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION, CONCENTRATE / ORAL0.2 mg/1mlExact identifier — unii candidate
68 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE / RESPIRATORY (INHALATION)NAExact identifier — unii candidate
40 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii candidate
81 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
88 equally ranked IID candidates
GLYCERYL MONOSTEARATEGLYCERYL MONOSTEARATE230OU9XXE4TABLET / ORAL33.34 mgExact identifier — unii candidate
21 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / TRANSDERMAL500 mgExact identifier — unii candidate
81 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 5 · 81 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
nystatinNYSTATINNuCare Pharmaceuticals,Inc.05cc72dd-8e05-bfb5-e063-6394a90a92f12026-08-19Adverse reactionsName fallback
generic name: NYSTATIN
nystatinNYSTATINPreferred Pharmaceuticals Inc.197e3046-3e58-4246-b260-f3995dce41a12026-08-05Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPreferred Pharmaceuticals Inc.d92f67a7-dcae-41c0-9a35-dbafa23611702026-08-04Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINA-S Medication Solutions98bd8ccb-0c68-47b9-bcb4-c5d8217868d92026-07-24Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPAI Holdings, LLC dba PAI Pharma28b4e26e-206a-4e8a-abfe-774b780e91c32026-07-21Adverse reactionsName fallback
generic name: NYSTATIN
NystopNYSTATINBryant Ranch Prepack0bb31239-fb77-442a-a9ee-ba61b45e7e682026-07-14Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINBryant Ranch Prepack2d2c4f79-95b5-417e-b5c1-8fac1dd09ddc2026-07-09Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPreferred Pharmaceuticals Inc.a97b4fa6-c1a7-4003-9321-3717eb640ea92026-07-06Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINKesin Pharma Corporation50737729-a4a4-e747-e063-6394a90adcc52026-06-30Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINBryant Ranch Prepack4f6f59fb-ae7d-48e5-b23e-a1d92160974f2026-05-11Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINTorrent Pharmaceuticals Limited4949dea7-d2b9-4e0d-974a-39408fa174ba2026-05-08Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINGenus Lifesciences Inc.b25cbae5-eaf5-4501-b013-02c778ca4a4e2026-05-07Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINTorrent Pharmaceuticals Limited559b5bd4-3564-4437-8d0a-fa3a972f8b832026-05-01Adverse reactionsName fallback
generic name: NYSTATIN
MycostatinNYSTATINDirect_Rxf1857ac0-806c-4a7e-e053-2995a90abbc02026-03-17Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINA-S Medication Solutionsf1b13a36-c349-4e26-a322-3ec02c6101552026-03-16Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINChartwell RX, LLC9954118e-abe6-4388-98c9-4473d39b2e282026-03-05Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINCardinal Health 107, LLCd59098da-1395-49fb-9fd6-947bbbeed56f2026-02-26Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINMajor Pharmaceuticals17b9e33d-da9c-467a-bbc4-9e257727f19a2026-02-23Adverse reactionsName fallback
generic name: NYSTATIN
Nystatin Oral SuspensionNYSTATINXttrium Laboratories, Inc.4a670371-d373-1ba6-e063-6394a90a13b62026-02-06Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINRedPharm Drug, Incf4c298d5-b012-7b56-e053-2a95a90a3d552026-01-24Adverse reactionsName fallback
generic name: NYSTATIN

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.